Recent Updates — LH
Labcorp Holdings Inc. disclosed that the Centers for Medicare & Medicaid Services released preliminary Clinical Laboratory Fee Schedule payment rates for 2027 through 2029 under PAMA. The company stated these rates are based on unrepresentative data and impose steep annual cuts threatening patient access, prompting continued support for the RESULTS Act. Labcorp reaffirmed its long-term outlook announced September 10, 2026: compound annual revenue growth of 5% to 8%, adjusted operating margin expansion of 75 to 150 basis points by end-2029, and adjusted EPS growth of 8.5% to 11.5%. The company expects to assess the CMS rates' impact on 2027 guidance in February 2027. Labcorp Holdings Inc. operates in the diagnostic laboratory services industry.
Labcorp Holdings Inc. hosted its 2026 Investor Day on September 10, 2026, reaffirming full-year 2026 guidance and providing a long-term financial outlook through 2029. The company expects compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. For 2026, Labcorp projects enterprise revenue between $14.71 billion and $14.83 billion, with adjusted earnings per share ranging from $18.10 to $18.55. The firm outlined strategic priorities focused on specialty testing in oncology, neurology, autoimmune diseases, and women’s health, alongside investments in artificial intelligence and robotics. Labcorp operates as a global leader of innovative and comprehensive laboratory services.
On August 11, 2026, Megan D. Bailey resigned as Executive Vice President and President of Central Laboratories and International, effective September 4, 2026. Brian J. Caveney, M.D., currently Executive Vice President and President of Early Development Research Laboratories and Chief Medical and Scientific Officer, will assume the role of Executive Vice President and President of Biopharma Laboratory Services and Chief Medical and Scientific Officer on September 1, 2026, overseeing both Early Development Research and Central Laboratories businesses. Labcorp Holdings Inc. operates in the healthcare industry, providing clinical laboratory services.